Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder

Sponsor
Anders Fink-Jensen, MD, DMSci
Study ID
NCT07523633
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Cannabis Abuse
  • Cannabis Addiction
  • Cannabis Dependence
  • Cannabis Use Disorder
  • Cannabis Use Disorders

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • semaglutide — DRUG
    semaglutide (Wegovy) once-weekly by subcutaneous injection, titrated to a maximum dose of 2.4 mg.
  • Placebo — DRUG
    once-weekly by subcutaneous injection of saline (BD Posiflush)

Study Details

The HASHTAG Study is investigating whether the medicine semaglutide can help adults with cannabis use disorder (CUD) reduce their cannabis use. Participants will be randomly assigned to receive either semaglutide or a placebo. The first 50 participants will have functional brain scans (fMRI) to investigate how the brain responds to cannabis-related cues. The main outcome after 20 weeks is whether semaglutide reduces cannabis use compared to placebo. Changes in brain activity in response to cannabis cues will be explored as a secondary outcome.

Key Dates

Start date
Apr 30, 2026
Status verified
May 2026
Primary completion
Apr 30, 2028
Completion
Apr 30, 2028

Study Design

Enrollment
100 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: semaglutide
    Wegovy (semaglutide) once-weekly by subcutaneous injection, titrated to a maximum dose of 2.4 mg
  • Placebo Comparator: Placebo (saline injection)
    Saline once-weekly by subcutaneous injection

Primary Outcome Measure

Cannabis consumption [ Time Frame: From baseline to week 20. ]

Central Contacts

Related Studies